Supernus hits Actavis with patent infringement claim
US-based specialty drugs company Supernus Pharmaceuticals has sued generics maker Actavis, accusing it of infringing three patents related to an antiepileptic drug.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
26 January 2026 The court found the board applied the wrong legal standard when evaluating Guardant Health’s obviousness challenge to a University of Washington DNA sequencing patent.